Devos, D. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009; 24: 993–1000.CrossRefGoogle ScholarPubMed

Nyholm, D, Klangemo, K, Johansson, A. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease. Eur J Neurol 2012; 19: 1079–85.CrossRefGoogle ScholarPubMed

Zibetti, M, Merola, A, Artusi, CA, et al. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience. Eur J Neurol 2014; 21: 312–8.Google Scholar

Samanta, J, Hauser, RA. Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert Opin Pharmacother 2007; 8: 657–64.Google Scholar

Fernandez, HH, Odin, P. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease. Curr Med Res Opin. 2011; 27: 907–19.CrossRefGoogle ScholarPubMed

Nyholm, D, Odin, P, Johansson, A, et al. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients. AAPS J 2013; 15: 316–23.Google Scholar

Nyholm, D, Askmark, H, Gomes-Trolin, C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003; 26: 156–63.Google Scholar

Olanow, CW, Kieburtz, K, Odin, P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014; 13: 141–9.CrossRefGoogle ScholarPubMed

Fernandez, HH, Vanagunas, A, Odin, P, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. Parkinsonism Relat Disord 2013; 19: 339–45.CrossRefGoogle ScholarPubMed

Espay, AJ. Management of motor complications in Parkinson disease: current and emerging therapies. Neurol Clin. 2010; 28: 913–25.Google Scholar

Hauser, RA, Ellenbogen, AL, Metman, LV, et al. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. Mov Disord 2011; 26: 2246–52.CrossRefGoogle Scholar

Hauser, RA, Hsu, A, Kell, S, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol 2013; 12: 346–56.Google Scholar

Pahwa, R, Lyons, KE, Hauser, RA, et al. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism Relat Disord 2014; 20: 142–8.Google Scholar

LeWitt, PA, Huff, FJ, Hauser, RA, et al. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. Mov Disord 2014; 29: 75–82.Google Scholar

LeWitt, PA, Friedman, H, Giladi, N, et al. Accordion pill carbidopa/levodopa for improved treatment of advanced Parkinson's disease symptoms [abstract]. 2013; 27 (Suppl. 1): S130–1.Google Scholar

Metman, LV, Stover, N, Cuiping, C, Cowles, VE, Sweeney, M. Improved motor performance associated with smoother levodopa time-concentration profiles with DM-1992, a gastroretentive, extended-release carbidopa/levodopa tablet, in patients with advanced Parkinson's disease. Neurology 2014; 82: poster 7.082.Google Scholar

Depomed Announces Positive Results from Phase 2 Study of DM-1992 for Parkinson's Disease [press release]. PHARMABIZ.COM, November 9, 2012.Google Scholar

Freed, MF, Grosset, D, Worth, P, et al. Rapid levodopa augmentation following inhaled CVT-301 results in rapid improvement in motor response when administered to PD patients in the OFF state. Neurology 2014; 82: S7.007.Google Scholar

Hauser, RA, Schwarzschild, MA. Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience. Drugs Aging 2005; 22: 471–82.CrossRefGoogle ScholarPubMed

Kanda, T, Jackson, MJ, Smith, LA, et al. Combined use of the adenosine A2A antagonist KW-6002 with l-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 2000; 162: 321–7.Google Scholar

Kase, H, Aoyama, S, Ichimura, M, et al. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease. Neurology 2003; 61 (Suppl. 6): S97–100.Google Scholar

Kalda, A, Yu, L, Oztas, E, Chen, JF. Novel neuroprotection by caffeine and adenosine A2A receptor antagonists in animal models of Parkinson's disease. J Neurol Sci 2006; 248: 9–15.CrossRefGoogle ScholarPubMed

Dungo, R, Deeks, ED. Istradefylline: first global approval. Drugs 2013; 73: 875–82.Google Scholar

Hauser, RA, Hubble, JP, Truong, DD, Istradefylline US-001 Study Group. Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD. Neurology 2003; 61: 297–303.Google Scholar

LeWitt, PA, Guttman, M, Tetrud, JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 2008; 63: 295–302.CrossRefGoogle ScholarPubMed

Stacy, M, Silver, D, Mendis, T, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 2008; 70: 2233–40.Google Scholar

Hauser, RA, Shulman, LM, Trugman, JM, et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord 2008; 23: 2177–85.CrossRefGoogle ScholarPubMed

Pourcher, E, Fernandez, HH, Stacy, M, et al. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism Relat Disord 2012; 18: 178–84.Google Scholar

Hauser, RA, Cantillon, M, Pourcher, E, et al. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol 2011; 10: 221–9.Google Scholar

Hauser, R, Sticchi, F, Rascol, O, et al. Phase-3 Clinical Trials of Adjunctive Therapy with Preladenant, an Adenosine 2a Antagonist, in Patients with Parkinson's Disease. American Academy of Neurology Annual Meeting; 2014;Google Scholar

Black, KJ CampBell, CM, Dickerson, W, et al., eds. A randomized, double-blind, placebo-controlled cross-over trial of the adenosine 2a antagonist SYN115 in Parkinson disease. Neurology; 2010; 82: poster P7.087.Google Scholar

Hauser, RA Olanow, CW, Kieburtz, KD, et al. A phase 2, placebo-controlled, randomized, double-blind trial of tozadenant (SYN-115) in patients with Parkinson's disease with wearing-off fluctuations on levodopa. Mov Disord 2013; 333 (Suppl. 1): e119.Google Scholar

Dall'Igna, OP, Porciuncula, LO, Souza, DO, Cunha, RA, Lara, DR. Neuroprotection by caffeine and adenosine A2A receptor blockade of β-amyloid neurotoxicity. Br J Pharmacol 2003; 138: 1207–9.Google Scholar

Stocchi, F, Borgohain, R, Onofrj, M, et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. Mov Disord 2012; 27: 106–12.CrossRefGoogle ScholarPubMed

Stocchi, F, Borgohain, R, Onofrj, M, et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. Mov Disord 2012; 27: 106–12.CrossRefGoogle ScholarPubMed

Gottwald, MD, Aminoff, MJ. Therapies for dopaminergic-induced dyskinesias in Parkinson disease. Ann Neurol 2011; 69: 919–27.Google Scholar

Pahwa, R, Tanner, CM, Hauser, RA, et al. Randomized trial of extended release amantadine in Parkinson's disease patients with levodopa-induced dyskinesia (EASED Study). Mov Disord 2013;28 (Suppl. 1): 443.Google Scholar

Lewitt, PA, Hauser, RA, Lu, M, et al. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology 2012; 79: 163–9.Google Scholar

Dimitrova, T, Bara-Jimenez, W, Savola, JM, et al. Alpha-2 adrenergic antagonist effects in Parkinson's disease. Mov Disord 2009; 24 (Suppl. 1): S261.Google Scholar

Johnston, TH, Fox, SH, McIldowie, MJ, Piggott, MJ, Brotchie, JM. Reduction of l-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Pharmacol Exp Ther 2010; 333: 865–73.CrossRefGoogle Scholar

Stocchi, F, Rascol, O, Destée, A, et al. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord 2013; 28: 1838–46.Google Scholar

Parkinson Study Group. Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Mov Disord 2013; 28: 1823–31.Google Scholar

Parkinson Study Group SURE-P Inbestigators, Schwarzschild, MA, Ascherio, A, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol 2014; 71: 141–50.Google Scholar